A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia.
第一作者:
Paolo,Strati
第一单位:
Department of Leukemia, The University of Texas M. D. Anderson Cancer Center , Houston, TX , USA.
作者:
主题词
成年人(Adult);老年人(Aged);老年人, 80以上(Aged, 80 and over);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);用药计划表(Drug Administration Schedule);红斑(Erythema);随访研究(Follow-Up Studies);粒细胞巨噬细胞集落刺激因子(Granulocyte-Macrophage Colony-Stimulating Factor);人类(Humans);白血病, 淋巴细胞, 慢性, B细胞(Leukemia, Lymphocytic, Chronic, B-Cell);中年人(Middle Aged);缓解诱导(Remission Induction);存活率分析(Survival Analysis);时间因素(Time Factors);治疗结果(Treatment Outcome)
DOI
10.3109/10428194.2014.974049
PMID
25311497
发布时间
2021-10-21
- 浏览12

Leukemia & lymphoma
1878-80页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文